{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:52:23Z","timestamp":1766908343838,"version":"3.37.3"},"reference-count":45,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["95\/2-9\/1"],"award-info":[{"award-number":["95\/2-9\/1"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2019,12,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Chronic Myeloid Leukaemia (CML) starts in certain blood-forming cells of the bone\nmarrow when cells acquire Philadelphia chromosome. Nowadays, scientists attempt to find novel and safe\ntherapeutic agents and approaches for CML therapy using Tyrosine Kinase Inhibitors (TKIs), CML\nconventional treatment agents, has some restrictions and also adverse effects. Recently, it has been proposed that\nphytochemicals, such as flavonoids due to their low side effects and notable safety have the potential to be used\nfor CML therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>K-562 cells were exposed with three concentrations of the querectin (10, 40 and\n80\u00b5M) for 12, 24 and 48 hours. After that, these cells apoptosis rate was estimated using Annexin-V\/PI staining\nand flowcytometry analysis, and their proliferation rate was evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5\ndiphenyl tetrazolium bromide (MTT). Finally, the expression of the 70 and 90 kilodalton heat shock proteins\n(HSP70 and 90), methionine adenosyltransferase 2A (MAT2A), Forkhead box protein M1 (FOXM1), caspase-3\nand -8, Bcl-X(L) and Bax involved in leukemic cells survival and proliferation was assessed using Real-Time\nPCR within 12, 24 and 48 hours after exposure with quercetin 40 and 80\u00b5M.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Considering consequences, querecetin induced apoptosis in K-562 cells, and also abrogated these cells\nproliferation. On the other hand, RT-PCR results showed a reduction in some of the candidate genes expression,\nespecially HSP70, Bcl-X(L) and FOXM1, when cells were treated with quercetin 40 and 80\u00b5M. Also, Bax,\ncaspase-3 and caspase-8 expression was significantly improved in K-562 cells upon quercetin exposure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> We concluded that CML therapy by querecetin due to its anti-proliferative and anti-survival\npotentials could lead to the promising therapeutic outcome through targeting major survival and proliferation\ninvolved genes expression.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520619666190729150442","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T06:55:03Z","timestamp":1564469703000},"page":"1523-1534","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1"],"prefix":"10.2174","volume":"19","author":[{"given":"Ali","family":"Hassanzadeh","sequence":"first","affiliation":[{"name":"Department of Immunology, Division of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Hosseinzadeh","sequence":"additional","affiliation":[{"name":"Department of Medical Genetic, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleheh","family":"Rezapour","sequence":"additional","affiliation":[{"name":"Department of Medical Genetic, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Vahedi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navideh","family":"Haghnavaz","sequence":"additional","affiliation":[{"name":"Department of Immunology, Division of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-7808","authenticated-orcid":true,"given":"Faroogh","family":"Marofi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Division of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1038\/sj.onc.1206082","volume":"21","author":"Salesse S.","year":"2002","unstructured":"Salesse S.; Verfaillie C.M.; BCR\/ABL: From molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002,21(56),8547-8559","journal-title":"Oncogene"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/onc.2010.409","volume":"30","author":"De Carvalho D.D.","year":"2011","unstructured":"De Carvalho D.D.; Binato R.; Pereira W.O.; Leroy J.M.; Colassanti M.D.; Proto-Siqueira R.; Bueno-Da-Silva A.E.; Zago M.A.; Zanichelli M.A.; Abdelhay E.; Castro F.A.; Jacysyn J.F.; Amarante-Mendes G.P.; BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011,30(2),223-233","journal-title":"Oncogene"},{"key":"ref=3","first-page":"981","volume":"47","author":"Chen Y.","year":"2018","unstructured":"Chen Y.; Wang T.; Du J.; Li Y.; Wang X.; Zhou Y.; The critical role of PTEN\/PI3K\/AKT signaling pathway in shikonin-induced apoptosis and proliferation inhibition of chronic myeloid leukemia. Cell. Physiol. Biochem.: Int. J. Experim. Cell. Physiol. Biochem Pharmacol 2018,47(3),981-993","journal-title":"Biochem Pharmacol"},{"key":"ref=4","first-page":"119","volume":"39","author":"Huang R.","year":"2018","unstructured":"Huang R.; Liu H.; Chen Y.; He Y.; Kang Q.; Tu S.; He Y.; Zhou X.; Wang L.; Yang J.; Wu A.; Li Y.; EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL\/PI3K\/AKT\/mTOR pathway. Oncol Rep 2018,39(1),119-128","journal-title":"Oncol Rep"},{"key":"ref=5","first-page":"8","volume":"76","author":"Frazer R.","year":"2007","unstructured":"Frazer R.; Irvine A.E.; McMullin M.F.; Chronic myeloid leukaemia in the 21 Century. Ulster Med J 2007,76(1),8-17","journal-title":"Ulster Med J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/asheducation-2017.1.115","volume":"2017","author":"Bhatia R.","year":"2017","unstructured":"Bhatia R.; Novel approaches to therapy in CML. Hematology (Am Soc Hematol Educ Program) 2017,2017(1),115-120","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","volume":"2017","author":"Mahon F.X.","year":"2017","unstructured":"Mahon F.X.; Treatment-free remission in CML: Who, how, and why? Hematology (Am Soc Hematol Educ Program) 2017,2017(1),102-109","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"Abruzzese E.","year":"2016","unstructured":"Abruzzese E.; Trawinska M.M.; de Fabritiis P.; Baccarani M.; Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol 2016,9(8),781-791","journal-title":"Expert Rev Hematol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"Hartmann J.T.","year":"2009","unstructured":"Hartmann J.T.; Haap M.; Kopp H.G.; Lipp H.P.; Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009,10(5),470-481","journal-title":"Curr Drug Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"Caldemeyer L.","year":"2016","unstructured":"Caldemeyer L.; Dugan M.; Edwards J.; Akard L.; Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep 2016,11(2),71-79","journal-title":"Curr Hematol Malig Rep"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","volume":"25","author":"Talati C.","year":"2018","unstructured":"Talati C.; Pinilla-Ibarz J.; Resistance in chronic myeloid leukemia: Definitions and novel therapeutic agents. Curr Opin Hematol 2018,25(2),154-161","journal-title":"Curr Opin Hematol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12185-018-2519-y","volume":"108","author":"Inoue A.","year":"2018","unstructured":"Inoue A.; Kobayashi C.I.; Shinohara H.; Miyamoto K.; Yamauchi N.; Yuda J.; Akao Y.; Minami Y.; Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Int J Hematol 2018,108(4),365-370","journal-title":"Int J Hematol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood.V128.22.4239.4239","volume":"128","author":"Tari Ashizawa A.","year":"2016","unstructured":"Tari Ashizawa A.; Ohanian M.; Cortes J.E.; BP1001, a novel therapeutic for chronic myelogenous leukemia. Blood 2016,128(22),4239","journal-title":"Blood"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1002\/jcp.27628","volume":"234","author":"Saraei R.","year":"2019","unstructured":"Saraei R.; Marofi F.; Naimi A.; Talebi M.; Ghaebi M.; Javan N.; Leukemia therapy by flavonoids: Future and involved mechanisms. J Cell Physiol 2019,234(6),8203-8220","journal-title":"J Cell Physiol"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23112922","volume":"23","author":"Bartma\u0144ska A.","year":"2018","unstructured":"Bartma\u0144ska A.; Tronina T.; Pop\u0142o\u0144ski J.; Milczarek M.; Filip-Psurska B.; Wietrzyk J.; Highly cancer selective antiproliferative activity of natural prenylated flavonoids. Molecules 2018,23(11)","journal-title":"Molecules"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1021\/jf8006568","volume":"56","author":"Benavente-Garc\u00eda O.","year":"2008","unstructured":"Benavente-Garc\u00eda O.; Castillo J.; Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008,56(15),6185-6205","journal-title":"J Agric Food Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13148-015-0095-z","volume":"7","author":"Busch C.","year":"2015","unstructured":"Busch C.; Burkard M.; Leischner C.; Lauer U.M.; Frank J.; Venturelli S.; Epigenetic activities of flavonoids in the prevention and treatment of cancer. Clin Epigenetics 2015,7(1),64","journal-title":"Clin Epigenetics"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.toxlet.2017.06.008","volume":"277","author":"Dekant W.","year":"2017","unstructured":"Dekant W.; Fujii K.; Shibata E.; Morita O.; Shimotoyodome A.; Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements. Toxicol Lett 2017,277,104-108","journal-title":"Toxicol Lett"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.3390\/nu10081089","volume":"10","author":"Grosso G.","year":"2018","unstructured":"Grosso G.; Effects of polyphenol-rich foods on human health. Nutrients 2018,10(8)","journal-title":"Nutrients"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/01635581.2014.894099","volume":"66","author":"Solmaz S.","year":"2014","unstructured":"Solmaz S.; Adan Gokbulut A.; Cincin B.; Ozdogu H.; Boga C.; Cakmakoglu B.; Kozanoglu I.; Baran Y.; Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells. Nutr Cancer 2014,66(4),599-612","journal-title":"Nutr Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2010.04.008","volume":"131","author":"Liu Y.L.","year":"2010","unstructured":"Liu Y.L.; Tang L.H.; Liang Z.Q.; You B.G.; Yang S.L.; Growth inhibitory and apoptosis inducing by effects of total flavonoids from Lysimachia clethroides Duby in human chronic myeloid leukemia K562 cells. J Ethnopharmacol 2010,131(1),1-9","journal-title":"J Ethnopharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.14735\/amko201629","volume":"29","author":"Klikova K.","year":"2016","unstructured":"Klikova K.; Pilchova I.; Stefanikova A.; Hatok J.; Dobrota D.; Racay P.; The Role of Heat Shock Proteins in Leukemia. Klin Onkol 2016,29(1),29-38","journal-title":"Klin Onkol"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121583","volume":"3","author":"Khan I.","year":"2018","unstructured":"Khan I.; Halasi M.; Patel A.; Schultz R.; Kalakota N.; Chen Y.H.; Aardsma N.; Liu L.; Crispino J.D.; Mahmud N.; Frankfurt O.; Gartel A.L.; FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight 2018,3(15)","journal-title":"JCI Insight"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0167-4889(01)00115-X","volume":"1540","author":"Halim A.B.","year":"2001","unstructured":"Halim A.B.; LeGros H.L.; Chamberlin M.E.; Geller A.; Kotb M.; Distinct patterns of protein binding to the MAT2A promoter in normal and leukemic T cells. Biochim Biophys Acta 2001,1540(1),32-42","journal-title":"Biochim Biophys Acta"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/sj.leu.2404391","volume":"20","author":"Steiner K.","year":"2006","unstructured":"Steiner K.; Graf M.; Hecht K.; Reif S.; Rossbacher L.; Pfister K.; Kolb H.J.; Schmetzer H.M.; Multhoff G.; High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006,20(11),2076-2079","journal-title":"Leukemia"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/757694","volume":"2015","author":"Khajapeer K.V.","year":"2015","unstructured":"Khajapeer K.V.; Baskaran R.; Hsp90 inhibitors for the treatment of chronic myeloid leukemia. Leukemia Res Treat 2015,2015","journal-title":"Leukemia Res Treat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/carcin\/bgq185","volume":"31","author":"Nakamura S.","year":"2010","unstructured":"Nakamura S.; Hirano I.; Okinaka K.; Takemura T.; Yokota D.; Ono T.; Shigeno K.; Shibata K.; Fujisawa S.; Ohnishi K.; The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 2010,31(11),2012-2021","journal-title":"Carcinogenesis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1002\/jcb.26052","volume":"118","author":"Mancini M.","year":"2017","unstructured":"Mancini M.; Castagnetti F.; Soverini S.; Leo E.; De Benedittis C.; Gugliotta G.; Rosti G.; Bavaro L.; De Santis S.; Monaldi C.; Martelli M.; Santucci M.A.; Cavo M.; Martinelli G.; FOXM1 transcription factor: A new component of chronic myeloid leukemia stem cell proliferation advantage. J Cell Biochem 2017,118(11),3968-3975","journal-title":"J Cell Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1158\/1078-0432.CCR-10-1565","volume":"16","author":"Cheng S.","year":"2010","unstructured":"Cheng S.; Gao N.; Zhang Z.; Chen G.; Budhraja A.; Ke Z.; Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax. Off. J Am Assoc Cancer Res 2010,16(23),5679-5691","journal-title":"J Am Assoc Cancer Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1179\/1607845412Y.0000000042","volume":"18","author":"Gokbulut A.A.","year":"2013","unstructured":"Gokbulut A.A.; Apohan E.; Baran Y.; Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology 2013,18(3),144-150","journal-title":"Hematology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11899-017-0404-z","volume":"12","author":"Narra R.K.","year":"2017","unstructured":"Narra R.K.; Flynn K.E.; Atallah E.; Chronic myeloid leukemia-the promise of tyrosine kinase inhibitor discontinuation. Curr Hematol Malig Rep 2017,12(5),415-423","journal-title":"Curr Hematol Malig Rep"},{"key":"ref=32","first-page":"929","volume":"37","author":"Yu L.","year":"2016","unstructured":"Yu L.; Wang H.B.; Jiang Q.; Patient reported outcome of tyrosine\nkinase inhibitor related side effects and their impact on daily life in\nChinese patients with chronic myeloid leukemia in the chronic\nphase. Zhonghua Xue Ye Xue Za Zhi = Zhonghua xueyexue zazhi, 2016,37(11),929-935","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua xueyexue zazhi,"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"Deremer D.L.","year":"2008","unstructured":"Deremer D.L.; Ustun C.; Natarajan K.; Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008,30(11),1956-1975","journal-title":"Clin Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3945\/ajcn.114.088708","volume":"100","author":"Cassidy A.","year":"2014","unstructured":"Cassidy A.; Huang T.; Rice M.S.; Rimm E.B.; Tworoger S.S.; Intake of dietary flavonoids and risk of epithelial ovarian cancer. Am J Clin Nutr 2014,100(5),1344-1351","journal-title":"Am J Clin Nutr"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10552-008-9144-7","volume":"19","author":"Lagiou P.","year":"2008","unstructured":"Lagiou P.; Rossi M.; Lagiou A.; Tzonou A.; La Vecchia C.; Trichopoulos D.; Flavonoid intake and liver cancer: A case-control study in Greece. Cancer Causes Control 2008,19(8),813-818","journal-title":"Cancer Causes Control"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3892\/mmr.2015.4672","volume":"13","author":"Woo S.M.","year":"2016","unstructured":"Woo S.M.; Choi Y.K.; Kim A.J.; Cho S.G.; Ko S.G.; p53 causes buteinmediated apoptosis of chronic myeloid leukemia cells. Mol Med Rep 2016,13(2),1091-1096","journal-title":"Mol Med Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/tox.22324","volume":"32","author":"Tsai T.C.","year":"2017","unstructured":"Tsai T.C.; Huang H.P.; Chang K.T.; Wang C.J.; Chang Y.C.; Anthocyanins from roselle extract arrest cell cycle G2\/M phase transition via ATM\/Chk pathway in p53-deficient leukemia HL-60 cells. Environ Toxicol 2017,32(4),1290-1304","journal-title":"Environ Toxicol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1007\/s13277-015-4118-3","volume":"37","author":"Adan A.","year":"2016","unstructured":"Adan A.; Baran Y.; Fisetin and hesperetin induced apoptosis and cell cycle arrest in chronic myeloid leukemia cells accompanied by modulation of cellular signaling. Tumour Biol 2016,37(5),5781-5795","journal-title":"Tumour Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejmech.2014.07.010","volume":"84","author":"Burmistrova O.","year":"2014","unstructured":"Burmistrova O.; Marrero M.T.; Est\u00e9vez S.; Welsch I.; Brouard I.; Quintana J.; Est\u00e9vez F.; Synthesis and effects on cell viability of flavonols and 3-methyl ether derivatives on human leukemia cells. Eur J Med Chem 2014,84,30-41","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1158\/1940-6207.CAPR-13-0383","volume":"7","author":"Maso V.","year":"2014","unstructured":"Maso V.; Calgarotto A.K.; Franchi G.C.; Nowill A.E.; Filho P.L.; Vassallo J.; Saad S.T.; Multitarget effects of quercetin in leukemia. Cancer Prev Res (Phila) 2014,7(12),1240-1250","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3892\/mmr.2015.4600","volume":"13","author":"Chen X.","year":"2016","unstructured":"Chen X.; Dong X.S.; Gao H.Y.; Jiang Y.F.; Jin Y.L.; Chang Y.Y.; Chen L.Y.; Wang J.H.; Suppression of HSP27 increases the antitumor effects of quercetin in human leukemia U937 cells. Mol Med Rep 2016,13(1),689-696","journal-title":"Mol Med Rep"},{"key":"ref=42","first-page":"346","volume":"25","author":"Lu H.Y.","year":"2017","unstructured":"Lu H.Y.; Chen J.; Du S.H.; Jia P.M.; Tong J.H.; Wu Y.L.; Zhou L.; Effects of quercetin on chronic myeloid leukemia cell line resistant to imatinib and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017,25(2),346-352","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"42571","DOI":"10.18632\/oncotarget.17246","volume":"8","author":"Russo M.","year":"2017","unstructured":"Russo M.; Milito A.; Spagnuolo C.; Carbone V.; Ros\u00e9n A.; Minasi P.; Lauria F.; Russo G.L.; CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. Oncotarget 2017,8(26),42571-42587","journal-title":"Oncotarget"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/01635581.2018.1380208","volume":"70","author":"Mutlu Altunda\u011f E.","year":"2018","unstructured":"Mutlu Altunda\u011f E.; Y\u0131lmaz A.M.; Ko\u00e7t\u00fcrk S.; Taga Y.; Yal\u00e7\u0131n A.S.; Synergistic induction of apoptosis by quercetin and curcumin in chronic myeloid leukemia (K562) cells. Nutr Cancer 2018,70(1),97-108","journal-title":"Nutr Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"45489","DOI":"10.18632\/oncotarget.9993","volume":"7","author":"He D.","year":"2016","unstructured":"He D.; Guo X.; Zhang E.; Zi F.; Chen J.; Chen Q.; Lin X.; Yang L.; Li Y.; Wu W.; Yang Y.; He J.; Cai Z.; Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models. Oncotarget 2016,7(29),45489-45499","journal-title":"Oncotarget"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T01:57:35Z","timestamp":1577152655000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173923\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520619666190729150442","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}